|
Numerical variable
|
TNFi (N = 71)
|
IL6-Ri (N = 78)
|
CTLA4-Ig (N = 58)
|
JAKi (N = 143)
|
p
|
|---|
|
Mean
|
SE
|
Mean
|
SE
|
Mean
|
SE
|
Mean
|
SE
|
|---|
|
Age
|
64.5
|
20.5
|
68.5
|
14.8
|
65.5
|
19.3
|
62.2
|
20.3
|
0.51
|
|
Disease duration (months)
|
169.1
|
135.7
|
171.7
|
129.3
|
191.8
|
152.7
|
167.5
|
131.5
|
0.18
|
|
CDAI
|
28.4
|
16.0
|
30.3
|
18.8
|
27.6
|
14.4
|
27.5
|
16.5
|
0.67
|
|
HAQ-DI
|
1.6
|
0.9
|
1.6
|
1.0
|
1.7
|
0.9
|
1.5
|
1.0
|
0.46
|
|
Dose of MTX (mg/week)
|
5.0
|
1.8
|
5.1
|
2.0
|
4.7
|
1.6
|
4.7
|
2.0
|
0.50
|
|
Dose of GC (mg/day)a
|
5.8
|
2.0
|
6.0
|
2.1
|
5.4
|
2.0
|
5.5
|
2.2
|
0.19
|
|
Serum creatinine (mg/dL)
|
0.9
|
0.7
|
0.9
|
0.8
|
0.7
|
0.4
|
0.7
|
0.4
|
0.10
|
- D2T RA difficult-to-treat rheumatoid arthritis, IPTW propensity-based inverse-probability treatment weighted, SE standard error, TNFi tumour necrosis factor inhibitor, IL-6Ri interleukin-6 receptor inhibitor, CTLA4-Ig cytotoxic T-lymphocyte–associated antigen-4 immunoglobulin, JAKi Janus kinase inhibitor, CDAI Clinical Disease Activity Index, HAQ-DI Health Assessment Questionnaire Disability Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS disease activity score, MTX methotrexate, GC glucocorticoid, ACPA anti-cyclic citrullinated peptide antibody
